Characteristic | AVETUX regimen |
n=39 | |
Sex, no. (%) | |
Male | 26 (67) |
Female | 13 (33) |
Age | |
Median years (range) | 62 (29–82) |
ECOG performance status, n (%) | |
0 | 28 (72) |
1 | 11 (28) |
Site of primary tumor, n (%) | |
Left (splenic flexure-rectum) | 36 (92) |
Right (transverse colon- caecum) | 3 (8) |
Microsatellite status, n (%) | |
MSI-H | 2 (5) |
MSI-L | 1 (3) |
MSS | 36 (92) |
Prior adjuvant chemotherapy, n (%) | |
Single agent fluoropyrimidine | 3 (8) |
Oxaliplatin based | 9 (23) |
Metastatic sites, n (%) | |
Liver | 30 (77) |
Lung | 12 (31) |
Lymph node (distant) | 18 (46) |
Bone | 3 (8) |
Other soft tissue | 5 (13) |
Ascites | 1 (3) |
Pleural effusions | 1 (3) |
Other | 7 (18) |
ECOG, Eastern Cooperative Oncology Group; MSI, microsatellite instability – high (H) or low (L); MSS, microsatellite stable.